HLA-A2+ melanomas express common melanoma-associated antigens (Ags) recognized in vitro by autologous cytotoxic T lymphocytes (CTL). However, it is not known whether tumor Ags can drive in vivo a selective accumulation/expansion of Ag-specific, tumor-infiltrating T lymphocytes (TIL). Therefore, to evaluate this possibility, 39 CTL clones isolated from several independent mixed lymphocyte tumor cultures (MLTC) of TIL and peripheral blood lymphocytes (PBL) of an HLA-A2+ melanoma patient and selected for T cell receptor (TCR)-dependent, HLA-restricted tumor lysis, were used for analysis of TCR α and β chain structure by the cDNA polymerase chain reaction (PCR) technique with variable gene-specific primers followed by sequencing. Despite absence of oligoclonality in fresh TIL and PBL, as well as in T cells of day 28 MLTC (day of cloning), sequence analysis of TCR α and β chains of TIL clones revealed a dominance of a major category of melanoma-specific, HLA-A2-restricted T cells expressing a Vα8.2/JαAP511/Cα and Vβ2.1/Dβ1/Jβ1.1/Cβ1 TCR. The same TCR was also found in 2 out of 14 PBL clones. The other PBL clones employed a Vα2.1 gene segment associated with either Vβ13.2, 14, or w22. Clones A81 (Vα2.1/JαIGRJα04/Cα and Vβ14/Dβ1/Jβ1.2/Cβ1) and A21 (Vα8.2/JαAP511/Cα and Vβ2.1/Dβ1/Jβ1.1/Cβ1), representative of the two most frequent TCR of PBL and TIL, respectively, expressed different lytic patterns, but both were HLA-A2 restricted and lysed only HLA-A2+ melanomas and normal melanocytes, thus indicating recognition of two distinct HLA-A2-associated and tissue-related Ags. Finally, by the inverse PCR technique, the specific TCR β chain (Vβ2.1/Dβ1/Jβ1.1/Cβ1) expressed by the dominant TIL clone was found to represent 19 and 18.4% of all Vβ2 sequences expressed in the fresh tumor sample and in the purified TIL, respectively, but + sequences expressed in PBL. These results are consistent with the hypothesis that a clonal expansion/accumulation of a melanocyte-lineage-specific and HLA-A2-restricted T cell clone occurred in vivo at the site of tumor growth.
|Number of pages||16|
|Journal||Journal of Experimental Medicine|
|Publication status||Published - Oct 1 1993|
ASJC Scopus subject areas